BALTIMORE–(BUSINESS WIRE)–LifeSprout, Inc., a privately held regenerative medicine company founded with technology licensed from Johns Hopkins University, today announced the appointment of Michael Kranda as CEO and member of the board of directors.
“We’re pleased to have attracted an executive of Michael’s caliber to lead LifeSprout at this pivotal time for the company as we proceed to leverage the full potential of our regenerative cell therapy platform,” said Sashank Reddy, M.D., Ph.D., co-founder of LifeSprout.
“I welcome the opportunity to lead the LifeSprout team, and collaborate with the thought leaders in tissue engineering, nano biotechnology, and materials science from Johns Hopkins to establish a new standard of bio stimulatory products for cell therapy applications,” said Kranda, LifeSprout, Inc. CEO.
Kranda comes to LifeSprout from gene therapy pioneer AskBio, where he served as SVP of Alliance Management and guided their central nervous system (CNS) gene therapy portfolio. Prior to joining AskBio, Kranda served as Senior Director of Business Development for the Allen Institute where he led efforts to establish partnerships initiatives in gene and cell therapy, and 3D machine learning enabled cell imaging. Kranda previously served as one of original board members for the Allen Institute for Brain Science as well as Managing Director of Vulcan Capital, Microsoft co-founder Paul Allen’s life science venture capital group. Prior positions in the industry include President of Immunex, CEO of Oxford GlycoSciences, and Director and Audit Committee Chairman for PTC Therapeutics.
About LifeSprout, Inc.
LifeSprout, Inc. is a privately held company developing revolutionary products for aesthetic and regenerative medicine. LifeSprout’s proprietary Regenerative Matrix platform comprises biomimetic, biocompatible materials engineered to look and feel like natural tissue. The first product from this platform — Lumina™ — is a next-generation aesthetic dermal filler that combines the proven safety of hyaluronic acid with bio stimulatory effects. LifeSprout is turning this technology into a suite of products for the millions of patients with tissue losses from aging, cancer, and orphan diseases. The Company is supported by Redmile Group, Triskelion Investments, Catalio Capital Management, Emerald Development Managers, and other leading institutional and family office firms.